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Structural and Functional Basis for p38-MK2-Activated Rsk Signaling
in Toll-Like Receptor-Stimulated Dendritic Cells
Rossana Zaru,a Alexander J. Edgar,a André Hanauer,b Colin Wattsa
Division of Cell Signalling and Immunology, College of Life Sciences, University of Dundee, Dundee, United Kingdoma; Institute of Genetics and Molecular and Cellular
Biology (IGBMC), Centre National de la Recherche Scientifique (UMR 7104), Institut National de la Santé et de la Recherche Médicale (U 964), University of Strasbourg,
Illkirch, Franceb
Rsk kinases play important roles in several cellular processes such as proliferation, metabolism, andmigration. Until recently,
Rsk activation was thought to be exclusively initiated by Erk1/2, but in dendritic cells (DC) Rsk is also activated by p38mitogen-
activated protein (MAP) kinase via its downstream substrates, MK2/3. How and why this noncanonical configuration of the
MAP kinase pathway is adopted by these key immune cells are not known.We demonstrate that the Erk1/2-activated C-terminal
kinase domain of Rsk is dispensable for p38-MK2/3 activation and show that compared with fibroblasts, a greater fraction of p38
andMK2/3 is located in the cytosol of DC prior to stimulation, suggesting a partial explanation for the operation of the nonca-
nonical pathway of Rsk activation in these cells. p38/MK2/3-activated Rsk phosphorylated downstream targets and is physiologi-
cally important because in plasmacytoid DC (pDC) stimulated with Toll-like receptor 7 (TLR7) agonists, Erk1/2 activation is
very weak relative to p38. As a result, Rsk activation is entirely p38 dependent. We show that this unusual configuration of MAP
kinase signaling contributes substantially to production of type I interferons, a hallmark of pDC activation.
Different cells share many signaling pathway components yetare able to propagate cell-specific signaling events leading to
distinct outcomes. How this is achieved is incompletely under-
stood. Inmost cells, a key pathway is theMek1/2-Erk1/2mitogen-
activated protein (MAP) kinase pathway leading to downstream
activation of many key substrates, including the MAP kinase-ac-
tivated kinasesMsk1/2 andRsk1 toRsk3 (reviewed in reference 1).
A striking feature of these closely related kinases is the presence of
distinct N- and C-terminal kinase domains (NTKD and CTKD)
with the latter playing a key role in activation of the former. The
seminal studies of this pathway showed that while Msk1/2 can be
activated by both Erk1/2 and p38MAPkinases (2), Rsk kinases are
exclusively activated by Erk1/2 (2). In earlier work, we demon-
strated an important exception to this rule in Toll-like receptor
(TLR)-stimulated murine dendritic cells (DC) by showing that
Rsk is also activated downstream of p38 signaling via the interme-
diate kinases MK2/3 (3). The two pathways for Rsk activation
converged at Ser380/386 in Rsk1 and -2, respectively, a key site
lying in a “hydrophobic motif” between the two kinase domains
that is responsible for recruitment of the NTKD-activating kinase
PDK1 (4, 5). In the canonical pathway, this key site is phosphor-
ylated in cis by the Rsk C-terminal kinase domain (CTKD) (6, 7),
whereas in the alternative pathway, the site is phosphorylated in
trans by MK2/3, apparently bypassing the CTKD (3). A CTKD-
independent pathway for Rsk activation was also demonstrated in
lipopolysaccharide (LPS)-stimulated macrophages (8).
Dendritic cells are crucial for the initiation of immune re-
sponses. They are able to sense pathogens and mount an appro-
priate immune response tailored to the pathogens encountered
(9). Due to their capacity to process and present pathogen-derived
antigens and produce pro- and anti-inflammatory cytokines, they
activate T lymphocytes. Several DC subsets such as plasmacytoid
DC (pDC) and conventional CD8 and CD8 DC have been
described (10). Although these different DC populations share
some similar features, they also have specific functions. For in-
stance, pDC respond to viral infection by producing large
amounts of type I interferons (IFN). DC sense pathogens through
several receptors such as those in the Toll-like receptor family that
recognize pathogen-derived products such as lipopolysaccharide
(LPS) (11, 12). The signaling cascades activated following TLR
engagement include the p38 and Erk1/2 pathways (13).
TLR expression is not limited to cells of the innate immune
system such as DC or macrophages but is also found in T and B
lymphocytes (14, 15) and indeed in nonimmune cells such as fi-
broblasts and endothelial and epithelial cells (12). Several studies
have shown that although these different cell types recognize the
same TLR ligand, their responses are unique. For instance, in B
cells, TLR9 stimulation induced not only the production of cyto-
kines, as in DC or macrophages but also their proliferation (16).
Apparently, the wiring of TLR signaling cascades is different in
different cell types.
In this study, we investigated several important questions
raised by our earlier finding of a p38-MK2/3-driven pathway of
Rsk activation in DC. For example, what are the structural re-
quirements for activation of Rsk when the CTKD is apparently
bypassed? Does the C-terminal region of Rsk still play a role? Do
Erk1/2-activated Rsk and p38-activated Rsk have the same down-
stream substrates? Also, since p38-MK2 signaling is intact in the
many cell types that activate Rsk exclusively via Erk1/2, what pre-
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vents the p38-MK2 signaling module from activating Rsk in these
cells? Perhaps most important, what is the functional significance
of p38-MK2-mediated Rsk activation? By comparing DC with
other immune and nonimmune cells, we provide some answers to
these questions.
MATERIALS AND METHODS
Mice and cell culture. Rsk2/ mice have been described previously in
reference 17. Bone marrow-derived dendritic cells (BMDC) were ex-
panded from C57BL/6 or Rsk2/ bone marrow using complete RPMI
1640 medium (cRPMI) supplemented with 10 ng/ml recombinant gran-
ulocyte-macrophage colony-stimulating factor (GM-CSF) (Peprotech) as
described in reference 18.Murine embryonic fibroblasts (MEF) were gen-
erated from C57BL/6 or Rsk2/mice and maintained as described pre-
viously (3). Bonemarrow-derivedmacrophages (BMM) were expanded
from bone marrow using complete Dulbecco modified Eagle medium
(DMEM) supplementedwith 30%L929 supernatant for 7 to 9 days. B cells
were isolated by negative selection from the spleen. Briefly, spleen cells
were incubated 30 min on ice with biotin-coupled anti-CD4, anti-CD8,
anti-CD11c, and anti-Ly6G antibodies (all from eBioscience). The cells
were washed and incubated with streptavidin Dynal beads (Invitrogen)
for 20min at room temperature. The cells were 91%positivewhen stained
with allophycocyanin (APC)-labeled anti-CD19 (eBioscience). pDCwere
generated from bone marrow in the presence of 100 ng/ml Flt3 ligand
(Flt3-L) (Peprotech) in cRPMI for 10 days. pDC (B200) were sorted on
an Influx cell sorter (BD Biosciences). Cells were 98% positive when
stained with fluorescein isothiocyanate (FITC)-labeled anti-B220 anti-
bodies (eBioscience). Animal work was overseen by a local Ethical Review
Committee and was conducted in accordance with United Kingdom
Home Office Project Licenses.
Retroviral constructs and retroviral infection of BMDC and MEF.
Moloney murine leukemia virus (MoMLV)-based pBMN-I-GFP (GFP
stands for green fluorescent protein) retroviral vector was provided by G.
Nolan, Stanford. Rsk2 was cloned from BMDC cDNA. A myc tag was
inserted at the N terminus by PCR (5=-ATGGAGCAGAAGCTGATCAG
CGAGGAGGACCTGCCGCTG GCGCAGCTGGC-3=). Full-length Rsk2
and truncated forms of Rsk2 were generated by PCR with the following
primers for the C-terminal region: 5=-TCACAGGGCTGTTGAGGTG-3=
for the full-length, myc-tagged Rsk2 (amino acids 1 to 740) [myc Rsk2
(1–740)], 5=-AAATGCGGCCGCACTCCGCTGAGCAAGAGTGGAGC
G-3= for myc Rsk2 (1–728), or 5=-TCAAATAGCAACAAAACTAAACCC
CC-3= formyc Rsk2 (1–390). The full-length and truncated forms of Rsk2
were cloned into the BamHI and NotI sites of pBMN-I-GFP. Virus was
produced by transfecting the Phoenix Eco 293T packaging cell line as
previously described (18). MEF were plated at 8  104 in 6-cm dishes.
After 24 h, cells were infected with 1 ml of virus supplemented with 5
g/ml Polybrene (Sigma). BMDC were infected at day 2 and day 3 with
viral supernatant supplemented with 8 g/ml Polybrene as described in
reference 18.
Cell stimulation and cell lysate preparation. A total of 106 BMDC or
BMMwere incubated for 5 h at 37°C in RPMI containing 0.3% fetal calf
serum (FCS) in 6-well plates. Cells left untreated or treated with either
dimethyl sulfoxide (DMSO) or 2 M PD184352 (provided by the Divi-
sion of Signal Transduction Therapy [DSTT], University of Dundee), 0.1
M BIRB796 (DSTT), 4 M BI-D1870 (kind gift of Boehringer-Ingel-
heimPharmaceuticals) for 30min, or 2MBIX02565 (kind gift of Boehr-
inger-Ingelheim Pharmaceuticals) for 1 h at 37°C, or 50 nM leptomycin B
(Merck Millipore) for 15 min at 37°C were stimulated for 30 min with
either 50 ng/ml LPS (Axxora) or 1 M CpG B (Invivogen) for 30 min or
with 1 g/ml R848 (Axxora) for 15 min at 37°C. MEF were starved over-
night at 37°C, pretreated with inhibitors as described above, and then
stimulatedwith 200ng/ml LPS for 30min at 37°C. PurifiedB cells (2 106
cells) were incubated in RPMI supplemented with 5% FCS for 1 h in
48-well plates. Inhibitors were added as described above followed by the
addition of 1 MCpG B for 30 min at 37°C. Sorted pDC (105 cells) were
incubated in 1.5-ml conical tubes for 1 h at 37°C in RPMI containing 2%
FCS. Inhibitors were added as described above followed by the addition of
1 g/ml R848 or 0.1 M CpG B for different lengths of time at 37°C.
Cells were washed once in cold phosphate-buffered saline (PBS) and
lysed in 1% Triton X-100 containing 50 mM Tris-HCl (pH 7.5), 1 mM
EGTA, 1 mM EDTA, 1 mM sodium orthovanadate, 10 mM sodium fluo-
ride, 5 mM sodium pyrophosphate, and 0.1% -mercaptoethanol and 1
tablet of protease inhibitors (Roche) for 10 min on ice. Lysates were cen-
trifuged for 10 min at 20,000 g at 4°C. Equal amounts of proteins were
loaded on 4 to 12% NuPage gels (Invitrogen) and then transferred onto
nitrocellulose membranes (Amersham). Membranes were probed with
the following antibodies. Antibodies to phosphorylated Rsk (p-Rsk)
(S386) and p-Rsk (S227) were from R&D Systems. Antibodies to p-Rsk
(T573) (clone 9346), Rsk2 (clone 9340), p-Erk1/2 (clone 9101), p-p38
(clone 9211), phosphorylated glycogen synthase kinase 3/ (p-
GSK3/) (S21/S9) (clone 9331), GSK3 (clone 9315), phosphorylated
filamin A (S2152) (clone 4761), p-MK2 (clone 2111), and MK2 (clone
3042) were from Cell Signaling. Antibodies to the myc tag (9E10; Milli-
pore), p-NHE1 (S703) (DSTT), NHE1 (catalog no. 611774; BD Biosci-
ence), and filamin A (H-300; Santa Cruz Biotechnology) were from the
indicated companies. In some experiments, lysates were precleared with
protein G-Sepharose (Amersham) and incubated with 2g of either anti-
RSK2, anti-NHE1, or anti-myc antibodies for 1 h at 4°C followed by the
addition of 15 l of protein G-Sepharose for 1 h at 4°C.
Microscopy. 2  105 BMDC or 50  104 MEF were plated on glass
coverslips in RPMI supplemented with 0.3% FCS or DMEM supple-
mented with 2 mg/ml bovine serum albumin (BSA) for 2 h or overnight,
respectively. The cells were fixed in 4% paraformaldehyde in PBS for 15
min and permeabilized with 100% ice-coldmethanol (MeOH) for 10min
on ice. After the cells were blocked with 1% BSA in Tris-buffered saline
(TBS), they were stained with either anti-p38, anti-MK2 or anti-MK3
antibodies (all from Cell Signaling) followed by Alexa Fluor 488-conju-
gated donkey anti-rabbit antibodies and 4=,6=-diamidino-2-phenylindole
(DAPI) (Invitrogen). Single optical sections were acquired on a confocal
microscope (LSM 700) using a 40 or 100 lens objective (Carl Zeiss,
Inc.).
Rsk kinase assay. BMDC were stimulated as described above, and
lysates were prepared as described above. The supernatant was frozen in
liquid nitrogen and stored at80°C. Endogenous Rsk2 was immunopre-
cipitated with 2 g of anti-Rsk2 antibodies (Santa Cruz Biotechnology).
Wild-type Rsk2 and mutant forms of Rsk2 were immune precipitated
from 25g of lysates with 2g of anti-myc coupled to protein G-Sephar-
ose for 30 min at 4°C. After 4 washes with buffer A (50 mMTris-HCl [pH
7.5], 0.1mMEGTA, and 0.1%-mercaptoethanol), the beads were resus-
pended in 50 mM Tris-HCl (pH 7.5), 0.1 mM EGTA, 0.1% -mercapto-
ethanol, 2.5 Mprotein kinase inhibitor (PKI) (TTYADFIASGRTGRRN
AIHD; peptide inhibitor of cyclic-AMP-dependent protein kinase), 10
mM magnesium acetate, 0.1 mM [	-32P]ATP, and Crosstide (GRPRTSS
FAEG; 30 M). The kinase assay was carried out for 30 min at 30°C and
then terminated and analyzed as described previously (19).
Cytokine production. pDC (7 104 cells) were incubated for 15 min
in 96-well round bottom plates in complete RPMI. Cells were either un-
treated or pretreatedwith 2MPD184352 orwith 0.1MBIRB796 for 30
min or with 2 MBIX02565 for 1 h at 37°C before being stimulated with
1 g/ml R848 (Axxora) for 18 h. The amount of interferon beta (IFN-)
was measured by enzyme-linked immunosorbent assay (ELISA) (IFN-;
R&D Systems).
RESULTS
Activation of Rsk by the p38 pathway is limited to some hema-
topoietic cells.We first confirmed and extended our earlier find-
ing that distinct pathways are used to activate Rsk inDCcompared
with other cell types such asMEF. Activation of Rsk requires phos-
phorylation of a key serine residue in a hydrophobicmotif (Ser380
and Ser386 in Rsk1 and Rsk2, respectively) which lies between the
Rsk Activation by MK2
January 2015 Volume 35 Number 1 mcb.asm.org 133Molecular and Cellular Biology
 o
n
 June 2, 2016 by UNIVERSITY LIBRARY-DUNDEE
http://m
cb.asm
.org/
D
ow
nloaded from
 
two kinase domains and recruits the NTKD-activating kinase
PDK1. As shown in Fig. 1A, stimulation of bone marrow-derived
DC (BMDC) with ligands for TLR4 (LPS), TLR9 (CpG), and
TLR7 (R848) resulted in robust phosphorylation of this site.How-
ever, in DC, Ser380/386 phosphorylation was resistant to inhibi-
tion of the Erk1/2 activating kinases MEK1/2 by PD184352 and
could be fully blocked only when the p38 MAP kinase inhibitor
BIRB0796 was also included (Fig. 1A). Control experiments showed
thatbothMAPkinasepathwayswere fully inactivatedby their respec-
tive inhibitors, because phosphorylation of Erk1/2 was completely
blockedbyPD184352andphosphorylationof thep38 substrateMK2
was fully inhibited by BIRB0796 (Fig. 1A). Interestingly, the nonca-
nonical p38 pathway of Rsk activation appeared more dominant for
Rsk2 than for Rsk1 (Fig. 1A). Sustained activation of Erk1/2 and p38
via TLR4 signaling depends on sequential involvement of 2 TLR
adaptors,MyD88andTRIF(20,21).Toassesswhetherp38-mediated
activation of RSK utilized one pathway in preference to the other, we
stimulated DC lacking MyD88 or TRIF. As shown in Fig. 1B, both
adaptor configurations of TLR4 were able to activate Rsk in a p38-
dependent, Erk1/2-independent fashion. These results contrasted
with the situation inmost other cell types, includingMEFwhere Rsk
activation, even by the same TLR stimulus, was due to Erk1/2 rather
thanp38 signaling (Fig. 1C). Taken togetherwith our earlier data (3),
these results show that noncanonical Rsk activation by p38/MK2/3
followingTLR signaling, is cell type specific rather thanTLR stimulus
specific.
As DC and fibroblasts have distinct origins and functions, we
next asked whether p38-driven Rsk activation was possible in
other cells of the hematopoietic lineage. We first looked in bone
marrow-derivedmacrophages (BMM), since they have the same
myeloid origin as DC. As in DC, Rsk activation was still observed,
albeit at a reduced level, when Erk1/2 signaling was blocked in
BMM and eliminated only when the p38 pathway was also sup-
pressed (Fig. 1D, left). Again, this wasmost clearly seen in the case
of Rsk2 (Fig. 1D). This is consistent with earlier results in LPS-
stimulated BMM showing persistent S386 phosphorylation in
the presence of an inhibitor of the Rsk CTKD (8). Next we looked
at B cells directly isolated from the spleen. Conversely to BMDC
andBMM, the contribution of the p38 pathway toRsk activation
in B cells was barely detectable (Fig. 1D, right). These results dem-
onstrate that while the Erk1/2 pathway of Rsk activation operates
in all cells, the capacity of p38 to activate Rsk is limited to certain
hematopoietic cells, notably DC and macrophages.
Structural requirements for p38-MK2/3 activation of Rsk.
We showed previously that p38 does not activate Rsk directly but
via its downstream effectorMK2/3, bypassing the requirement for
theRskCTKD.However, theC-terminal portion of Rskmight still
be needed to permit noncanonicalMK2/3 phosphorylation of Rsk
either because it is involved inmaintaining a favorable conforma-
tion of the hydrophobic motif of Rsk and/or because it harbors a
binding site, either for MK2/3 or an adaptor that brings MK2/3
together with Rsk. To determine the structural requirements for
the p38-MK2/3 pathway of Rsk2 activation, we generated a series
of truncation mutants some of which are shown in Fig. 2A. Pro-
gressive deletion from the C terminus first removed residues
known to be required for Rsk binding to Erk1/2, including 2 crit-
ical arginine residues (22) to yield Rsk2 (1–728). We generated a
further mutant lacking the C-terminal kinase domain and a sub-
stantial part of the linker region [Rsk2 (1–390)]. These Rsk mu-
tants were myc tagged and cloned into retroviral vectors to allow
expression in primary Rsk2-null DC. The cells were stimulated
with LPS, and phosphorylation of Ser386 was measured along
with the phosphorylation sites in the CTKD andNTKDwhich are
targeted by Erk1/2 (S577) and PDK1 (S227), respectively. As ex-
pected, the full-length, myc-tagged Rsk2 (1–740) was phosphory-
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FIG 1 Rsk activation by the p38 pathway is restricted to BMDC and BMM.
Immunoblot analysis of the phosphorylation of Rsk1/2 at Ser380/386, Erk1/2,
and MK2. (A and B) Wild-type (A and B), Myd88/ (B), or Trif/ (B)
BMDCwere left untreated () or stimulated () with LPS (50 ng/ml) or CpG
B (1 M) for 30 min or R848 for 15 min (leftmost portion of panel A). The
lysates were immunoprecipitated (IP) with Rsk1/2 antibodies. (C) MEF were
left untreated or stimulated with LPS (200 ng/ml) for 30min. (D) BMM or B
cells were left untreated or stimulated with LPS (50 ng/ml) or CpG B (1 M)
for 30 min. (A to D) Cells were stimulated in the presence () or absence ()
of 2MPD184352 or 0.1MBIRB0796. The results shown are representative
of the results from at least three independent experiments.
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lated on all these sites in response to LPS signaling (Fig. 2B). Phos-
phorylation of S577 was blocked as expected by PD184352, while
phosphorylation of S386 and S227 was blocked only in the pres-
ence of PD184352 and BIRB0796, consistent with Erk1/2- and
p38-driven activation pathways in DC (Fig. 2B). Removal of the
Erk1/2 binding site [Rsk2 (1–728)] prevented phosphorylation of
S577 but not phosphorylation of S386 or S227. Remarkably, phos-
phorylation of these two key residues was sustained in the more
drastically truncated forms of Rsk2 (Fig. 2B), which lack all of the
C-terminal domain andmuch of the linker region [Rsk2 (1–390)].
Moreover, loss of the CTKD in Rsk2 (1–390) rendered Rsk acti-
vation completely resistant to PD184352 and fully sensitive to
BIRB0796 (Fig. 2B). In other words, these truncations produced a
formof Rsk that is exclusively activated by the p38 pathway inDC.
These results demonstrate that the C-terminal region of Rsk is
dispensable for Rsk activation in DC. To assess whether the trun-
cated forms of Rskwere catalytically active as implied by sustained
phosphorylation of S386 and S227, we isolated myc-tagged Rsk2
(1–390), Rsk2 (1–728), Rsk2 (1–740) as well as endogenous Rsk2
and tested their kinase activity in vitro. As shown in Fig. 2C, LPS
stimulated the activity of both the truncated Rsk2 products.
Moreover, in contrast to full-length Rsk2, blockade of the p38
pathway substantially inhibited activation of truncated Rsk2 lack-
ing the Erk1/2 binding domain or the C-terminal kinase domain
(Fig. 2C). These results contrasted dramatically with those ob-
tained inMEF where neither Rsk2 (1–728) or Rsk2 (1–390) could
be phosphorylated by LPS (Fig. 2D).
Distinct partitioning of p38, MK2/3, and Rsk in DC may
partly explain its unusual mode of activation. Since most cells
express p38, MK2/3, and Rsk isoforms, it is surprising that the
noncanonical pathway of Rsk activation under study here is con-
fined to DC andmacrophages. One possibility is that these hema-
topoietic cells express an adaptor protein that brings MK2/3 and
Rsk together. Although the truncation analysis reported above
does not eliminate this possibility, it would limit the regions of Rsk
that could engage such an adaptor to the NTKD and part of the
linker region. Another possibility is that the spatial distribution of
p38,MK2/3, and Rsk isoforms is distinct in DC andmacrophages.
In fibroblasts,MK2 and probablyMK3 are located predominantly
in the nucleus as a complex with p38 due to the presence of
nuclear localization sequence (NLS) motifs in MK2/3 proteins
(23, 24). Upon activation, p38 phosphorylatesMK2, unmasking
the MK2 nuclear export sequence, which results in the cytoplas-
mic relocalization of the p38/MK2 complex (24, 25). We com-
pared the localization ofMK2,MK3, and p38 in BMDC andMEF.
In MEF, p38 was present in both the cytoplasm and nucleus,
whereas MK2 and MK3 were localized in the nucleus (Fig. 3A).
Upon stimulation, p38 accumulated in the nucleus, andMK2 and
MK3 translocated into the cytoplasm, as previously described. Re-
markably, in resting BMDC,MK2 andMK3were not only present
in the nucleus but were also found in the cytoplasm (Fig. 3A). As
in MEF, the remaining nuclear pool of MK2/3 translocated into
the cytoplasm upon activation of p38 by LPS.
We hypothesized that the striking constitutive cytosolic loca-
tion of MK2/3 prior to activation by p38 in DCmight be relevant
toMK2/3-driven Rsk activation in these cells. To test this, we took
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FIG 2 CTKD and Erk1/2 binding domain are dispensable for Rsk activation by the p38 pathway. (A) Wild type and truncated forms of myc Rsk2. NTKD,
N-terminal kinase domain; CTKD, C-terminal kinase domain; E, Erk1/2 binding domain. (B) Rsk2/ BMDC were reconstituted with the indicated myc Rsk2
constructs. Cells were left untreated or were stimulated with LPS (50 ng/ml) for 30 min in the presence or absence of 2 M PD184352 or 0.1 M BIRB0796.
Immunoblots were analyzed for Rsk phosphorylation at Ser577, Ser386, and Ser227. The results shown are representative of the results of three independent
experiments. (C) Endogenous Rsk2 (left) and myc Rsk2 constructs (right) activity in BMDC left untreated or treated with LPS (50 ng/ml) for 30 min in the
presence or absence of 0.1 M BIRB0796. Data are the means 
 standard deviations (SD) (error bars) of duplicate experiments and are representative of the
results from two independent experiments. (D) Rsk2/MEF infected with the indicated myc Rsk2 constructs were left untreated or stimulated with LPS (200
ng/ml) for 30 min. Rsk2 phosphorylation was analyzed by immunoblotting with anti-p-Rsk (Ser386). The positions of the different myc Rsk2 constructs are
indicated by black arrows to the left of the blots. The positions of molecular mass markers (in kilodaltons) are shown to the right of the blots. The results shown
are representative of the results from two independent experiments.
Rsk Activation by MK2
January 2015 Volume 35 Number 1 mcb.asm.org 135Molecular and Cellular Biology
 o
n
 June 2, 2016 by UNIVERSITY LIBRARY-DUNDEE
http://m
cb.asm
.org/
D
ow
nloaded from
 
advantage of the inhibitor leptomycin B, which blocks the nucleus-
to-cytosol export of proteins (24), reasoning that if cytoplasmic
MK2/3 were responsible for Rsk phosphorylation in BMDC, its
upstream activation by p38 and downstream activation of Rsk
should be resistant to leptomycin B. Indeed, as shown in Fig. 3,
MK2/3 phosphorylation in response to LPS was abolished by p38
inhibition as expected but was resistant to leptomycin B (Fig. 3B).
This contrasted with previous data which showed that in 293T
cells a form of MK2 that lacked the NLS, and therefore was local-
ized in the cytoplasm, could not be activated (23). Importantly,
phosphorylation of S386 on Rsk2 was also resistant to leptomycin
B given alone or in combination with the Erk1/2 pathway inhibi-
tor PD184352 (Fig. 3B). Leptomycin B was active in these exper-
iments, because leptomycin B treatment induced the accumula-
tion of greater amounts of MK2 in the DC nucleus (Fig. 3C).
However, some remained in the cytosol, and consistent with this,
even prolonged leptomycin B treatment did not inhibit Rsk2 S386
phosphorylation (data not shown). Taken as a whole, these results
demonstrate an atypical cytosolic localization of p38/MK2/3 in
DCand show that p38-drivenRsk activation inDCdidnot require
nuclear export of p38/MK2/3. Whether the differential localiza-
tion of the upstream activators of Rsk in DC fully accounts for the
noncanonical pathway will require further investigation.
Erk1/2- and p38-activated Rsk may utilize partially distinct
substrates. Using three well-characterized Rsk substrates, the
Na/H transporter NHE1 (26), the cytoskeletal protein filamin
A (27), and the Ser/Thr kinase GSK3/ (28), we asked whether
the pathway of Rsk activation affected substrate preference. As
shown in Fig. 4, phosphorylation of Ser707 onNHE1was strongly
enhanced by LPS signaling and almost completely blocked by the
Rsk inhibitor BI-D1870 (29) or BIX02565 (30). Our recent results
show that the latter compound is a more specific and reliable Rsk
inhibitor (19). Rsk-dependent phosphorylation of NHE1 per-
sisted when either the Erk1/2 pathway or p38 pathway was
blocked by PD184352 or BIRB0796, respectively, and eliminated
only when both pathways were inhibited (Fig. 4). Thus, NHE1 can
be phosphorylated by either canonically (Erk1/2) or noncanoni-
cally (MK2/p38) activated Rsk. Interestingly, the situation was
FIG 3 Constitutive cytoplasmic MK2/3 mediates Rsk phosphorylation. (A) MK2 and MK3 localization in MEF or BMDC left untreated or stimulated with
anisomycin (10 ng/ml) or LPS (50 ng/ml) for 30 min. The cells were fixed, permeabilized, and stained with anti-p38, anti-MK2, or anti-MK3 antibodies.
Fluorescence was analyzed on a LSM700 Zeiss confocal microscope. The images shown are representative of the images from three independent experiments.
Bars, 20 m. (B) BMDC were left untreated or stimulated with LPS (50 ng/ml) for 30 min in the absence or presence of 2 MPD184352, 0.1 MBIRB0796, or
50 nM leptomycin B. Phosphorylation of Ser386 from immunoprecipitated Rsk2 was analyzed by immunoblotting. Cell lysates were immunoblotted for
p-Erk1/2, p-MK2, and total Rsk2. The blots shown are representative of the blots from three independent experiments. (C) BMDC were stimulated as in panel
B either in the absence or presence of 50 nM leptomycin B (LB), and MK2 localization was analyzed by immunofluorescence. The images shown are represen-
tative of the images from three independent experiments. Bars, 20 m.
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different for filamin A and GSK3. LPS-stimulated phosphoryla-
tion of filamin A on Ser2152 was reduced to background level by
inclusion of PD184352 and unaffected by BIRB0796, while
GSK3/ phosphorylation on Ser21/Ser9 was predominantly
blocked by PD184352 and fully blocked by the combined inhibi-
tion of Erk1/2 and p38 pathways. Thus, while NHE1 in DC ap-
pears to be fully phosphorylated via either canonical or nonca-
nonical pathways of Rsk activation, filamin A and most GSK3
appear to be phosphorylated only by the canonical Erk1/2-depen-
dent pathway.
In pDC, Rsk is mainly activated by the p38 pathway and is
involved in IFN- production.Our results thus far identify some
of the structural requirements for p38-driven Rsk activation and
indicate how this pathway might operate in DC but not in other
cells. They also show that p38-MK2/3-activated Rsk can phos-
phorylate downstream substrates. However, there are additional
important questions. For example, are there physiological situa-
tions that take advantage of this pathway of Rsk activation and
what outputs in DC require Rsk signaling? Together, these ques-
tions imply that DC may need to respond to stimuli that prefer-
entially activate the p38 pathway rather than the Erk1/2 pathway
and that those responses require Rsk activation.
In BMDC, activation of both Erk1/2 and p38 by TLR ligands is
strong and sustained (3, 18), but these cells do not fully represent
DC subset heterogeneity in vivo. Other culture systems generate
additional DC types, including pDC which respond to viral infec-
tion by producing large amounts of type I IFN.We expanded pDC
from bone marrow precursors using Flt3 ligand (31) and stimu-
lated themwith theTLR7 ligandR848. As shown in Fig. 5A, Erk1/2
phosphorylation was weak and transient, whereas p38 phosphor-
ylation was strong and more sustained. Similar results were ob-
tained in pDC stimulated with the TLR9 ligand, CpG (Fig. 5D).
Analysis of Rsk phosphorylation showed that despite weak Erk1/2
activation, it was also strong and sustained.Moreover, blockade of
the p38 pathway prevented Rsk activation in pDC (Fig. 5B and E).
Thus, in pDC stimulated with TLR7 or TLR9 agonists, Rsk activa-
tion was completely p38 dependent. Next we investigated MAP
kinase pathway requirements for pDC responses to TLR signaling.
We stimulated pDC in the presence of MAP kinase or Rsk inhib-
itors andmeasured IFN- production. As shown in Fig. 5C and F,
production of this cytokine was unaffected by suppression of
Erk1/2 signaling, consistent with weak activation of this pathway,
but highly sensitive to inhibition of the p38 pathway. Importantly,
IFN- production was also substantially inhibited by the Rsk in-
hibitor BIX02565. Thus, p38-driven Rsk signaling is critical for
optimal activation of this hallmark pDC response.
DISCUSSION
We previously identified a novel configuration of theMAP kinase
pathway in DC whereby the p38-activated kinase MK2 or MK3
activates Rsk, thus bypassing the canonicalmode of Rsk activation
which requires the C-terminal kinase domain (CTKD). The path-
ways converge at Ser386 (Rsk2) in the hydrophobic motif, which
then recruits PDK1, leading to NTKD activation and downstream
substrate phosphorylation. It is worth noting that Rsk CTKD and
MK2/3, which, respectively, phosphorylate Ser386 in the ca-
nonical and noncanonical configuration, are closely related
phylogenetically (1). These earlier results left unanswered sev-
eral important questions concerning the structural basis of
p38/MK2/3-driven activation of Rsk, its apparent restriction to
DC, and its physiological significance.We have addressed some
of these questions here.
We found that the CTKD and downstream Erk1/2 binding
domain were dispensable for Rsk activation in DC and that dele-
tion of these regions created a form of Rsk that was exclusively
p38/MK2/3 activated. Whether the MK2/3 interaction with Rsk2
is facilitated by a yet unidentified scaffolding protein or is tran-
sient and unassisted is not clear.We tried to coimmunoprecipitate
MK2/3 with Rsk but observed only small amounts of MK3 asso-
ciated with Rsk following LPS stimulation. It appears that the
interaction of Rsk2 with MK2/3 is weaker than that with Erk1/2,
transient, and perhaps stimulus dependent. Among the cell types
we tested, noncanonical Rsk activation was observed in DC and
macrophages but not in B cells or MEF. The operation of the
pathway inmacrophages is consistent with the results of an earlier
study (8).
Seeking a potential explanation for cell type-specific differ-
ences inRsk activation pathways, we observed a striking difference
in the distribution of MK2 and MK3 between DC and MEF. In
MEF, most MK2/3 were found in the nucleus, whereas in DC, a
substantial proportion was also localized to the cytosol and there-
fore topologically accessible to Rsk. Leptomycin B, which blocks
the export ofMK2/3 from the nucleus in other cell types (24), had
no effect on LPS-stimulated, MK2-dependent Rsk activation in
DC.MK2 andMK3 shuttle between the nucleus and cytosol, but at
steady state, they reside principally in the nuclei of most cells, the
NLS dominating over a nuclear export signal (NES) whose core
residues are sequestered in the catalytic core until activation re-
leases this domain (24, 32, 33). How this balance is altered in DC,
favoring a constitutive cytosolic pool of MK2/3, merits further
investigation. Conceivably, a binding partner exists thatmasks the
nuclear localization sequence on MK2/3 and/or the NES is func-
tional in the absence of upstream phosphorylation.
Although the distinct distribution of p38 and MK2/3 in DC is
likely to be relevant to the operation of the noncanonical pathway,
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FIG 4 Rsk activated by the canonical and noncanonical pathways utilize par-
tially distinct substrates. BMDCwere left untreated or stimulated with LPS (50
ng/ml) for 30 min in the absence or presence of 2 M PD184352, 0.1 M
BIRB0796, 2 M BIX02565, or 4 M BI-D1870. NHE1 was immunoprecipi-
tated, and phosphorylationwas analyzed by immunoblotting. Cell lysates were
immunoblotted for phosphorylated filamin A (p-FLNa), total FLNa,
p-GSK3/, and total GSK3/. The results shown are representative of the
results from three independent experiments.
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the initial experimental results suggest that simply relocating
MK2/3 to the cytosol is not sufficient to establish noncanonical
activation of Rsk in fibroblasts. We expressed MK2 carrying mu-
tations that render it both constitutively active (24) and due to
inactivation of the NLS, located in the cytosol of NIH 3T3 cells.
However, Rsk was not activated under these conditions. One pos-
sibility is that other factors expressed only in myeloid cells are
additionally needed to bridge p38/MK2/3 and Rsk.
In most cells, p38 activates three of the four MAP kinase-acti-
vated kinases, MK2/3, Msk1/2, and Mnk1/2 (1), whereas in DC,
MK2/3 connects p38 to an additional fourth group of downstream
kinases, the Rsks. The existence of this pathway has two implica-
tions. The first implication is that there are instances inDC and/or
macrophages where Rsk signaling is required but the canonical
upstreamErk1/2 pathway is only weakly activated, and the second
is that there are important outputs of Rsk signaling in DC. Differ-
ential activation of p38 versus Erk1/2 MAP kinases by different
TLR stimuli has been reported inDCwhere TLR4 or TLR5 ligands
promoted stronger p38 activation and TLR2 signaling drove
stronger Erk1/2 activation (34). Also, in human CD14 mono-
cytes stimulated with a TLR8 agonist, p38 activation was much
stronger than Erk1/2 activation, whereas in the CD14dim mono-
cyte subset, the situation was reversed (35). We found a clear
example of weak Erk1/2 activation in pDC stimulated with the
TLR7 agonist R848 and TLR9 agonist CpG B. pDC are an impor-
tant subset of DC that execute several immunological functions
but are particularly associated with production of type I IFNs that
are crucial in antiviral responses (36). In complete contrast to the
situation in, for example, fibroblasts, Rsk activation in pDC
downstream of TLR7 signaling was entirely driven by the p38
pathway andwasminimally affected, if at all, by Erk1/2 inhibition.
This important result illustrates that there is considerable plastic-
ity in the “wiring” of theMAP kinase pathway and that paradigms
established in cell lines and in other primary cells do not apply
universally.We further show that p38 inhibition blocks type I IFN
production in pDC stimulated with a TLR7 ligand and that Rsk
activity downstream of p38 is important for this response. Relo-
cating the principal domain of p38/MK2/3 activation from the
nucleus to the cytosol increases the number of potential substrates
for the p38 pathway in DC, and Rsk may not be the only pathway
to benefit. For example, in a recent study, it was shown that in
macrophagesMK2 is implicated in the phosphorylation of Akt1/2
(37) though probably indirectly through modulation of mem-
brane PIP3 levels. The p38/MK2/3/Rsk pathway operating in DC
may have another important role in inflammatory cytokine sig-
naling. Although Erk1/2 and p38 pathways have both been impli-
cated in the regulation of cytokine production, several studies
have shown that the intensity of Erk1/2 activation generally cor-
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FIG 5 The p38 pathway activates Rsk in pDC. (A andD) pDCwere stimulatedwith 1g/ml R848 (A) or with 0.1MCpGB (D) for the indicated lengths of time
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relates with the amount of the anti-inflammatory cytokine inter-
leukin-10 (IL-10) produced which in turn can have an inhibitory
effect on the production of proinflammatory cytokines (38). The
p38 pathway has been shown to exert negative feedback on Erk1/2
activation (39, 40), but the mechanism is not fully characterized.
Because Rsk is known to yield negative feedback on Erk1/2 activity
(29, 41, 42), we speculate that p38-driven activation of Rsk also
serves to suppress Erk1/2 activation. In other words, the nonca-
nonical pathway under study here may serve to further polarize
MAP kinase activity away from Erk1/2 and toward p38.
Several studies, including some studies of DC (43, 44) have
shown that blockade of p38 suppresses type I IFN production, but
to our knowledge, our results are the first to show a link between
Rsk activity and production of these key inflammatory cytokines.
Further studies are needed to explore this link. mTOR (mamma-
lian target of rapamycin) might be relevant here, since an earlier
study reported that inhibition of mTOR, or some of its down-
streammediators, prevented interferon regulatory factor 7 (IRF7)
activation by TLR9 and consequently inhibited IFN-/ produc-
tion (45). Rsk can activate mTOR by inactivating Tsc1/2, which
acts as a GTPase-activating protein (GAP) for the mTOR-activat-
ing GTPase Rheb (46).
Finally, unregulated production of type I IFNs may lead to DC
and B cell activation in the context of autoimmunity, and indeed,
pDC responses to self rather than pathogen-derived nucleic acids
have been linked to pathologies such as systemic lupus erythema-
tosus and psoriasis (47). A great deal of attention has been focused
on suppressing inflammatory cytokines through p38 inhibition
(13). Our results imply that Rsk might be considered an alterna-
tive downstream drug target in situations where type I IFNs are
linked to pathology.
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